Liraglutide for the treatment of obesity
Obesity and being overweight have become significant global health concerns, and may actually be seen as chronic disease conditions or even as a worldwide epidemic. In addition to the necessary life-style modifications required to effect weight-loss, which constitutes an essential healthcare interve...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2016-05-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4496 |
| _version_ | 1811161334518120448 |
|---|---|
| author | Elmien Bronkhorst Natalie Schellack |
| author_facet | Elmien Bronkhorst Natalie Schellack |
| author_sort | Elmien Bronkhorst |
| collection | DOAJ |
| description | Obesity and being overweight have become significant global health concerns, and may actually be seen as chronic disease conditions or even as a worldwide epidemic. In addition to the necessary life-style modifications required to effect weight-loss, which constitutes an essential healthcare intervention in this patient population, the use of adjunctive pharmacotherapeutic agents is often required. This article provides an overview of the first injectable treatment option, namely liraglutide, in the management of obesity, or of patients that are overweight in the presence of significant co-morbid conditions. |
| first_indexed | 2024-04-10T06:12:39Z |
| format | Article |
| id | doaj.art-3745ee3710f8448e9be896d7113ed4e8 |
| institution | Directory Open Access Journal |
| issn | 2078-6190 2078-6204 |
| language | English |
| last_indexed | 2024-04-10T06:12:39Z |
| publishDate | 2016-05-01 |
| publisher | AOSIS |
| record_format | Article |
| series | South African Family Practice |
| spelling | doaj.art-3745ee3710f8448e9be896d7113ed4e82023-03-02T11:51:46ZengAOSISSouth African Family Practice2078-61902078-62042016-05-0158310.4102/safp.v58i3.44963630Liraglutide for the treatment of obesityElmien Bronkhorst0Natalie Schellack1Department of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University (SMU)Department of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University (SMU)Obesity and being overweight have become significant global health concerns, and may actually be seen as chronic disease conditions or even as a worldwide epidemic. In addition to the necessary life-style modifications required to effect weight-loss, which constitutes an essential healthcare intervention in this patient population, the use of adjunctive pharmacotherapeutic agents is often required. This article provides an overview of the first injectable treatment option, namely liraglutide, in the management of obesity, or of patients that are overweight in the presence of significant co-morbid conditions.https://safpj.co.za/index.php/safpj/article/view/4496liraglutideoverweightobesityweight-lossincretinglp-1type 2 diabetes mellitus |
| spellingShingle | Elmien Bronkhorst Natalie Schellack Liraglutide for the treatment of obesity South African Family Practice liraglutide overweight obesity weight-loss incretin glp-1 type 2 diabetes mellitus |
| title | Liraglutide for the treatment of obesity |
| title_full | Liraglutide for the treatment of obesity |
| title_fullStr | Liraglutide for the treatment of obesity |
| title_full_unstemmed | Liraglutide for the treatment of obesity |
| title_short | Liraglutide for the treatment of obesity |
| title_sort | liraglutide for the treatment of obesity |
| topic | liraglutide overweight obesity weight-loss incretin glp-1 type 2 diabetes mellitus |
| url | https://safpj.co.za/index.php/safpj/article/view/4496 |
| work_keys_str_mv | AT elmienbronkhorst liraglutideforthetreatmentofobesity AT natalieschellack liraglutideforthetreatmentofobesity |